Rabies mRNA Vaccine

Rabies mRNA Vaccine Download the case study as a pdf: Contact Us Please complete the form below for any commercial, partnering, media, press, or general inquiries. If you need to contact our customer service team, please click on the button below. Contact the customer service

Read More

Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

Press Release Univercells acquires Synhelix, entering into synthetic biology and the race to next-generation DNA synthesis January 13, 2022 Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable and automated DNA synthesis technology resulting in one-step generation of long DNA fragments, at…

Read More

Quantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics

Press Release Quantoom Biosciences granted $13.9 million (€12.4 million), to support the development of its novel MRNA manufacturing platform for vaccines and therapeutics December 20, 2021 The objective is to make RNA therapeutics accessible to global patient populations. Makes large-scale decentralized RNA production economically viable. Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to…

Read More

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

Press Release Etherna Immunotherapies and Quantoom Biosciences announce a strategic collaboration for the development of a novel RNA production system June 29, 2021 The objective is to make RNA therapeutics accessible to global patient populations. Makes large scale decentralized RNA production economically viable. eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies with in-house…

Read More